Head to Head Survey: Synlogic (SYBX) and ChemoCentryx (CCXI)

Synlogic (NASDAQ: SYBX) and ChemoCentryx (NASDAQ:CCXI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability and analyst recommendations.

Earnings & Valuation

This table compares Synlogic and ChemoCentryx’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Synlogic N/A N/A -$26.26 million ($9.43) -1.01
ChemoCentryx $11.94 million 37.33 -$39.96 million ($0.60) -15.23

Synlogic has higher earnings, but lower revenue than ChemoCentryx. ChemoCentryx is trading at a lower price-to-earnings ratio than Synlogic, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Synlogic and ChemoCentryx, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Synlogic 0 1 3 0 2.75
ChemoCentryx 0 1 1 0 2.50

Synlogic presently has a consensus target price of $18.75, indicating a potential upside of 96.54%. Given Synlogic’s stronger consensus rating and higher probable upside, equities analysts plainly believe Synlogic is more favorable than ChemoCentryx.

Profitability

This table compares Synlogic and ChemoCentryx’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Synlogic N/A -50.19% -46.76%
ChemoCentryx N/A -67.57% -20.43%

Insider and Institutional Ownership

64.2% of Synlogic shares are held by institutional investors. Comparatively, 48.7% of ChemoCentryx shares are held by institutional investors. 18.6% of Synlogic shares are held by insiders. Comparatively, 26.2% of ChemoCentryx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Synlogic has a beta of 2.91, suggesting that its share price is 191% more volatile than the S&P 500. Comparatively, ChemoCentryx has a beta of 2.02, suggesting that its share price is 102% more volatile than the S&P 500.

Summary

Synlogic beats ChemoCentryx on 7 of the 11 factors compared between the two stocks.

About Synlogic

Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.

About ChemoCentryx

ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply